Elevated Cardiac Troponin T in Patients With Skeletal Myopathies

Johannes Schmid(Medical University of Graz), Laura Liesinger(BioTechMed-Graz), Ruth Birner‐Gruenberger(Medical University of Graz), Tatjana Stojaković(Medical University of Graz), Hubert Scharnagl(Medical University of Graz), Benjamin Dieplinger(Convent Hospital of the Brothers of Saint John of God), Martin Asslaber(Medical University of Graz), Roman Radl(Medical University of Graz), Meinrad Beer(University Hospital Ulm), Malgorzata Polacin(University Hospital Ulm), Johannes Mair(Innsbruck Medical University), Dieter Szolar(Medical University of Graz), Andrea Berghold(Medical University of Graz), Stefan Quasthoff(Medical University of Graz), Josepha Binder(Medical University of Graz), Peter P. Rainer(Medical University of Graz)
Journal of the American College of Cardiology
April 1, 2018
Cited by 224Open Access
Full Text

Abstract

BACKGROUND: Cardiac troponins are often elevated in patients with skeletal muscle disease who have no evidence of cardiac disease. OBJECTIVES: The goal of this study was to characterize cardiac troponin concentrations in patients with myopathies and derive insights regarding the source of elevated troponin T measurements. METHODS: Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) concentrations were determined by using high sensitivity assays in 74 patients with hereditary and acquired skeletal myopathies. Patients underwent comprehensive cardiac evaluation, including 12-lead electrocardiogram, 24-h electrocardiogram, cardiac magnetic resonance imaging, and coronary artery computed tomography. cTnT and cTnI protein expression was determined in skeletal muscle samples of 9 patients and in control tissues derived from autopsy using antibodies that are used in commercial assays. Relevant Western blot bands were subjected to liquid chromatography tandem mass spectrometry for protein identification. RESULTS: Levels of cTnT (median: 24 ng/l; interquartile range: 11 to 54 ng/l) were elevated (>14 ng/l) in 68.9% of patients; cTnI was elevated (>26 ng/l) in 4.1% of patients. Serum cTnT levels significantly correlated with creatine kinase and myoglobin (r = 0.679 and 0.786, respectively; both p < 0.001). Based on cTnT serial testing, 30.1% would have fulfilled current rule-in criteria for myocardial infarction. Noncoronary cardiac disease was present in 23%. Using cTnT antibodies, positive bands were found in both diseased and healthy skeletal muscle at molecular weights approximately 5 kDa below cTnT. Liquid chromatography tandem mass spectrometry identified the presence of skeletal troponin T isoforms in these bands. CONCLUSIONS: Measured cTnT concentrations were chronically elevated in the majority of patients with skeletal myopathies, whereas cTnI elevation was rare. Our data indicate that cross-reaction of the cTnT immunoassay with skeletal muscle troponin isoforms was the likely cause.


Related Papers

No related papers found

Powered by citation graph analysis